Article Information
History
- September 9, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Arantxa Valdiviaa,
- Ignacio Torresa,
- Víctor Latorreb,
- Clara Francés-Gómezb,
- Eliseo Alberta,
- Roberto Gozalbo-Rovirac,
- María Jesús Alcaraza,
- Javier Buesaa,c,
- Jesús Rodríguez-Díazc,
- Ron Gellerb and
- David Navarroa,c
- aMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
- bInstitute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia, Spain.
- cDepartment of Microbiology, School of Medicine, University of Valencia, Valencia, Spain.
- *Correspondence:
David Navarro, Microbiology Service, Hospital Clínico Universitario, and Department of Microbiology, School of Medicine, Av. Blasco Ibáñez 17, 46010 Valencia, Spain. Phone: +34 963864657; Fax: +3963864173; E-mail: david.navarro{at}uv.es.
Posted September 09, 2020.
Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays
